3 Things About BioNTech That Smart Investors Know
Since the early days of the pandemic, a group of biotech companies have seen their stocks tied tightly to the prospects of a COVID-19 vaccine. The potential windfall from a successful drug simply overwhelmed any value of future programs.
More than 18 months later, Moderna and BioNTech (NASDAQ: BNTX) -- along with its partner Pfizer (NYSE: PFE) -- have captured much of the benefit after being the first to receive authorization late last year. Still, BioNTech can get overlooked when discussing inoculations, and many people even call its drug the "Pfizer vaccine." That misnomer is just one of the things you'll uncover when digging a little deeper into the German biotech company.
Image source: Getty Images.
Source Fool.com
